Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

BLUE BELL, Pa., Jan. 27, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock. The shares of common stock and warrants were sold in units consisting of one share of common stock and 0.5 of a warrant to purchase one share of common stock at a price of $1.15 per unit. The warrants have a term of five years and an exercise price of $1.40 per share. Inovio may call these warrants if the closing bid price of the common stock has been at least $2.80 over 20 trading days and certain other conditions are met.

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

The gross proceeds of the offering were $24.3 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by Inovio, were approximately $23.0 million. Roth Capital Partners acted as the sole placement agent in the offering. Brean Murray, Carret & Co. and Rodman & Renshaw, LLC served as financial advisors to the Company in the offering.

Inovio intends to use proceeds from the offering for further development of its DNA vaccine against cervical dysplasias and cancer, other preclinical and clinical studies, and general corporate purposes.

The securities described above were offered by Inovio pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission and a prospectus supplement previously filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may b
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... AUSTIN, Texas , July 30, 2015 ... solutions company focused on gynecologic disease, announced ... 2015 financial results after the market close ... an investor conference call and webcast at ... August 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
(Date:7/30/2015)... July 30, 2015  NanoSmart Pharmaceuticals, Inc., a ... has received Orphan Drug Designation from the Food ... product that uses NanoSmart,s proprietary drug delivery platform. ... for the treatment of Ewing,s sarcoma, a rare ... NanoSmart,s Orphan Drug Designation on the basis of ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... the release dated August 24, 2011 with the following ... and should read: The Company will provide attendees an ... Form 8K with the SEC after the close of ...  This presentation will also be available at http://ir.questcor.com/sec.cfm ...
... DOYLESTOWN, Pa., Sept. 1, 2011 ProPhase Labs (NASDAQ: ... be donating $1,000 to a well-deserving, locally nominated and ... their "Share Your Cause, Not Your Cold" contest, hosted ... registered, qualified and valid non-for-profit organization organized under the ...
Cached Medicine Technology:UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 2UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 3Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 2Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 3
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... ... The Venetian on Grace Bay in the Turks & Caicos Islands is pleased to announce ... 40% on their stay while enjoying some of the most beautiful ocean views in the ... a chance to reconnect with loved ones and rediscover one's best self. The sea ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see the ... a serious challenge. Because of growing competition, it is more important than ever ... , The team at Wound Care Advantage has found that while ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Two ... people with the rare bone marrow disorder called myelofibrosis. ... brand name Jakafi, won,t cure myelofibrosis, it can help ease ... to the studies. "This is probably the most ...
... report published this week in the New England Journal ... melanoma patients with a specific genetic mutation benefit from the ... to 15.9 months. In patients who responded, the drug stopped ... patients with a BRAF V600 mutation, this drug is a ...
... of Traumatic Brain Injury Research at Kessler Foundation, is an ... on March 6, 2012, in Washington, DC. Dr. Grafman ... brain injury. A well known expert, he will focus on ... injury and genetic polymorphisms on social abilities and quality of ...
... Colin Farrelly wants to see more research into remarkable ... live 100 years disease-free. He describes the current pathology-based ... biology" and suggest more resources should be focused on ... the question ,what causes disease?, is the most significant ...
... -- Strict enforcement of underage drinking laws reduces the ... new study suggests. State lawmakers have relied heavily on ... of alcohol under the legal age laws -- to control ... on young people aged 15 to 24 from the FBI,s ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... FDA mandate that would have forced tobacco companies to ... The proposed requirement from the U.S. Food and Drug ... would have emblazoned cigarette packaging with images of people ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
... Designed for High Throughput Screening ... of assays into HTS by sharing ... performance of Analyst AD, fluorescence intensity, ... Optimized for seamless integration into ...
... features for assay development and basic ... Reduces the inevitable transfer time required ... developed to meet the challenges of ... unparalleled detection performance for Fluorescence Intensity, ...
Medicine Products: